Abacus Global Management, Inc.
ABX · NYSE
Analyst ratings
hold · 1 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 13, 2026 | Piper Sandler | Maintains | Neutral | $13.00 |
| May 8, 2026 | Piper Sandler | Maintains | Neutral | $10.00 |
| April 7, 2026 | Piper Sandler | Maintains | Neutral | $9.50 |
Valuation and share price sustainability
The stock has demonstrated strong validation of its intrinsic value, delivering a 73% gain over 18 months and surpassing InvestingPro's fair value target of $11.99. Analyst consensus targets average $14.08, representing a 34% spread above the last close, with B. Riley and Texas Capital maintaining positive ratings citing robust growth potential.
The stock's rich earnings multiple and tight interest coverage raise concerns about sustainability. Fair value community estimates span from very low to $15, suggesting deep disagreement on worth, with one expert report implying the share price may already be too high relative to fundamentals and near-term earnings catalysts.
Tokenization of life insurance assets as a growth driver
Abacus has already tokenized over 100 in-force policies and plans to migrate its entire balance sheet portfolio on-chain by year-end 2026. This positions the company as a first mover in digitizing a $224 billion secondary life insurance market, potentially unlocking significant liquidity, investor access, and high-margin revenue streams.
Execution risk on new strategic initiatives, including tokenization, remains a key swing factor for the stock. The near-term EPS consensus has not yet reflected benefits from these efforts, and integration of new leadership alongside unproven blockchain-based insurance products introduces material operational uncertainty.
Earnings growth trajectory and revenue expansion outlook
Abacus is forecast to grow earnings at 30% per annum and EPS at 34.2% annually, significantly outpacing both the broader U.S. market and the insurance sector. Multiple quarters have already shown revenue growth exceeding 90%, with Q3 2025 posting 124% year-over-year expansion, reinforcing confidence in the company's compounding growth profile.
Revenue growth is forecast at only 13.1% annually, falling short of the 20% high-growth threshold, and the company's return on equity remains undetermined. Piper Sandler's Crispin Love maintains only a Neutral rating despite raising the price target, reflecting skepticism that current growth rates justify a more constructive stance.